Post by PPD

For small biotech companies, every development decision carries weight. A single enrollment delay, protocol amendment or regulatory setback can impact timelines, funding and long-term program viability. The challenge isn't execution alone. It's having the right expertise, infrastructure and insight in place early enough to make confident decisions. Learn why small biotech companies are rethinking how they approach clinical development — and why a global CRO may be the ideal partner. ⬇️